SynthesisAntimicrobial resistance and infection control2025
The role of infection prevention and control in the mitigation of human-to-human transmission of Nipah virus: a systematic review.
Synthesis in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hendra and Nipah viruses: Biosafety evidence for risk-based containment, inactivation practices, and one health preparedness.One health (Amsterdam, Netherlands) · 2026Review
- Nipah virus in the era of global connectivity: molecular evolution, transmission risk, and preparedness strategies.Virus genes · 2026Review
- Assessing the pandemic potential of Nipah virus: From molecular pathogenesis to ecological spillover risks.Infectious medicine · 2026Review
- Nipah virus infection: what clinicians need to know.Le infezioni in medicina · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDetected first in humans in 1998, Nipah virus (NiV) has produced regular outbreaks with high mortality rates in Southeast Asia. Outbreaks are often driven by human-to-human transmission, posing an infection risk to both the wider community and healthcare workers who care for NiV cases. Infection prevention and control (IPC) practices are key to preventing amplification of disease outbreaks and protecting both healthcare workers and other patients, but significant evidence gaps exist in the identification of specific modes of NiV transmission that occur in outbreaks and the effectiveness of currently recommended IPC practices against NiV.
methodsA literature search was conducted, retrieving studies from PubMed, Embase, and medRxiv. Following screening, 32 eligible studies were included in the review. Selected studies described the modes of transmission identified in NiV outbreaks, effectiveness of IPC practices against NiV and specific risk factors for NiV transmission. A meta-analysis of NiV transmission exposure risk factors was subsequently conducted.
resultsNiV transmission was identified following various types of contact with cases, including direct contact, touching body fluids and contact with a case after death. A minority of cases were responsible for most transmission events, with 94 cases (67%) with identified transmission routes generated from 6 cases (4%). No comparative studies were found that assessed IPC effectiveness, but several studies described examples of shortcomings in IPC provision in NiV outbreaks. Meta-analysis identified contact with a NiV case as a significant risk factor for transmission.
conclusionsIdentification of multiple modes of human-to-human transmission stresses the importance of adherence to recommended IPC practices when caring for NiV patients. Several nosocomial outbreaks coincided with deficiencies in the wearing of personal protective equipment, hand hygiene, and surface cleanliness. The successful application of updated global IPC recommendations would represent a significant advancement of global preparedness for NiV outbreaks to prevent disease transmission and reduce the risk of a NiV epidemic or pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.